Daniel Zelterman

Professor

Yale School of Public Health

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daniel Zelterman is a Professor at Yale University School of Public Health, United States. His research areas include statistical methods in health data analysis, dehumanization and elder abuse, cancer therapy resistance, and climate data extremes. He has contributed to various recent articles focusing on Bayesian statistical designs, clinical trial methodologies, and the impact of structural ageism on violence against older persons.

Articles (11)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Mariaelena Pierobon

Associate Professor

George Mason University

UNITED STATES

View details

Joan Monin

UNITED STATES

View details

Wei Wei

Assistant Professor

Yale University School of Medicine

UNITED STATES

View details

Denise Esserman

Yale School of Public Health

UNITED STATES

View details

Lance A Liotta

Distinguished University Professor

George Mason University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniel Zelterman

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

The Maximum Negative Hypergeometric Distribution

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

Regression methods for the appearances of extremes in climate data

Bayesian local exchangeability design for phase II basket trials

Implicit and Explicit Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity

A phase i study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1/PD-L1

Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

Impact of structural ageism on greater violence against older persons: A cross-national study of 56 countries

Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints

Accounting for multiple comparisons in statistical analysis of the extensive bioassay data on glyphosate

Correcting for multiple comparisons in statistical analysis of animal bioassay data

Collaborators (5)

Mariaelena Pierobon

Joan Monin

Wei Wei

Denise Esserman

Lance A Liotta

Make your next move.